Wockhardt was in action on Monday after the drug maker said the US health regulator agreed to abridged clinical trials for antibiotic being developed by the company. Wockhardt recorded a jump of 6.46 percent in share price on Monday.
The company is developing superdrug antibiotic WCK 5222. The drug is expected to be a life-saving therapy for serious hospital acquired infections. The aforesaid US FDA approval will help Wockhardt to speed up phase III clinical trials for the drug.